Pliant Therapeutics Past Earnings Performance
Past criteria checks 0/6
Pliant Therapeutics's earnings have been declining at an average annual rate of -41.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 11.3% per year.
Key information
-41.3%
Earnings growth rate
63.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -11.3% |
| Return on equity | -39.4% |
| Net Margin | -1,273.3% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pliant Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 10 | -123 | 40 | 97 |
| 30 Sep 22 | 10 | -113 | 34 | 91 |
| 30 Jun 22 | 10 | -109 | 32 | 87 |
| 31 Mar 22 | 7 | -103 | 30 | 80 |
| 31 Dec 21 | 8 | -97 | 28 | 78 |
| 30 Sep 21 | 10 | -92 | 25 | 77 |
| 30 Jun 21 | 13 | -81 | 22 | 72 |
| 31 Mar 21 | 15 | -75 | 20 | 71 |
| 31 Dec 20 | 42 | -42 | 17 | 66 |
| 30 Sep 20 | 94 | 18 | 15 | 60 |
| 30 Jun 20 | 90 | 19 | 13 | 54 |
| 31 Mar 20 | 86 | 20 | 12 | 50 |
| 31 Dec 19 | 57 | -7 | 11 | 47 |
| 31 Mar 19 | 0 | -43 | 8 | 31 |
| 31 Dec 18 | 0 | -35 | 7 | 24 |
Quality Earnings: 9PT is currently unprofitable.
Growing Profit Margin: 9PT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9PT is unprofitable, and losses have increased over the past 5 years at a rate of 41.3% per year.
Accelerating Growth: Unable to compare 9PT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9PT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 9PT has a negative Return on Equity (-39.36%), as it is currently unprofitable.